ANONYMOUS: "History of Changes for Study: NCT04644068 - Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)", 19 November 2020 (2020-11-19), XP055875100, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT04644068?A=1&B=1&C=merged#StudyPageTop> [retrieved on 20211221] (B1)

ANONYMOUS: "Study Record Versions History of Changes for Study: NCT04644068 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)", 19 November 2020 (2020-11-19), XP055875178, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT04644068?A=1&B=1&C=merged#StudyPageTop> [retrieved on 20211221] (B1)

WO-A1-2021/013735 (B1)

STANISZEWSKA A D ET AL: "The novel PARP1-selective inhibitor, AZD5305, is efficacious as monotherapy and in combination with standard of care chemotherapy in the in vivo preclinical models", CANCER RESEARCH 20210701 AMERICAN ASSOCIATION FOR CANCER RESEARCH INC. NLD, vol. 81, no. 13 SUPPL, 1 July 2021 (2021-07-01), XP009532404, ISSN: 1538-7445 (B1)

HU XIAO-LONG ET AL: "Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer", PHYTOMEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 50, 5 September 2018 (2018-09-05), pages 88 - 98, XP085539127, ISSN: 0944-7113, DOI: 10.1016/J.PHYMED.2018.09.012 (B1)